Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $13.32M fell 69.3% year over year, behind the -54.8% change in trailing-twelve-month research & development. Sequentially, it fell 14.5% from the prior quarter. Over 3 fiscal years it compounded at +4.0% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -69.3% toward the trailing-twelve-month pace of -54.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 109.16M USD
- Year-over-year change
- -35.5%
- 4-year CAGR
- +8.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.16M | -35.5% |
| FY2024 | 2024-12-31 | 169.31M | +32.5% |
| FY2023 | 2023-12-31 | 127.8M | +31.8% |
| FY2022 | 2022-12-31 | 96.94M | +25.0% |
| FY2021 | 2021-12-31 | 77.55M | — |
Research & Development vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 research & development of $79.04M is the 6th highest of the 10 companies compared; the peer median is $99.41M.
- Its year-over-year change of -54.8% is the lowest of 10, against a peer median of -8.9%.
- Over three fiscal years its annual growth of +4.0% compares with a peer median of +6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68B | +26273.1% | +50.2% | 46313.4% | |
| LTM Mar 2026 | $151.37M | -38.7% | +6.7% | 152.0% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $108.76M | -25.2% | -14.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M | +115.1% | +40.7% | — |
| LTM Mar 2026 | $79.04M | -54.8% | +4.0% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $71.8M | +27.7% | +16.5% | — |
| LTM Mar 2026 | $70.7M | -6.3% | +29.5% | — | |
| LTM Mar 2026 | $30.07M | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | $12.86M | -17.9% | -24.0% | 9596.3% | |
| Peer median (excluding PLRX) | $99.41M | -8.9% | +6.7% | 422.2% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.7M |
| Gross Profit | 7.57M | 9.69M | 1.58M | 0 | (1.7M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M |
| Selling, General & Admin | 27.56M | 39.95M | 57.93M | 59.06M | 47.22M |
| Operating Expenses | 105.11M | 136.89M | 185.73M | 228.37M | 148.38M |
| Depreciation & Amortization | 1.54M | 3.68M | 1.84M | 2.13M | 1.7M |
| EBITDA | (95.73M) | (118.85M) | (158.23M) | (205.16M) | (145.09M) |
| EBITDA Margin | -1264.2% | -1227.1% | -10014.4% | — | — |
| Operating Income | (97.54M) | (127.2M) | (184.15M) | (228.37M) | (150.07M) |
| Operating Margin | -1288.1% | -1313.4% | -11654.7% | — | — |
| Interest Income | 272K | 4.67M | 24.08M | 21.09M | 0 |
| Interest Expense | 0 | 791K | 1.27M | 3.02M | 2.56M |
| Other Income / Expenses | 272K | 3.88M | 22.81M | 18.06M | 729K |
| Income Before Tax | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Pre-Tax Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Net Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (Basic) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| EPS (Diluted) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| Weighted Avg Shares | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
| Weighted Avg Shares (Diluted) | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.